Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-thymocyte globulin (Thymoglobulin Thymo) in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone Marrow Transplant
Autors principals: Al-Kadhimi, Z, Gul, Z, Abidi, M, Lum, LG, Deol, A, Chen, W, Jang, H, Ozust, C, Langston, A, Waller, E, Uberti, J
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857176/
https://ncbi.nlm.nih.gov/pubmed/28581472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2017.95
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars